Abstract
Key market catalysts in the fourth quarter of 2012 include an expected decision by the US Food and Drug Administration (FDA) on the approval of cabozantinib for thyroid cancer; top-line results from a trial of re-treatment with the peptide NX-1207 in benign prostatic hypertrophy (BPH); and top-line results from Abbott's Phase II AVIATOR trial examining various interferon-free regimens for the treatment of hepatitis C virus (HCV) infection.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
